Core Insights - Nurix Therapeutics reported significant advancements in its clinical programs, including the presentation of updated data for bexobrutideg and the extension of collaborations with Sanofi and Gilead [1][2][3] Clinical Developments - Updated Phase 1 clinical data for bexobrutideg (NX-5948) showed an objective response rate (ORR) of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with durable responses and a favorable safety profile [3][4] - The FDA cleared the IND application for GS-6791/NX-0479, a novel IRAK4 degrader, allowing Gilead to initiate Phase 1 trials [1][3] - The European Medicines Agency granted Orphan Drug Designation to bexobrutideg for lymphoplasmacytic lymphoma, providing incentives for its development [5] Financial Performance - Revenue for the fiscal quarter ended May 31, 2025, was $44.1 million, a significant increase from $12.1 million in the same quarter of 2024, primarily due to a $30 million license revenue from bexobrutideg [6][9] - Research and development expenses rose to $78.1 million from $48.9 million year-over-year, reflecting increased clinical and manufacturing costs [8][9] - The net loss for the quarter was $43.5 million, or $0.52 per share, compared to a net loss of $44.5 million, or $0.71 per share, in the prior year [9][10] Strategic Collaborations - Sanofi extended its license for Nurix's STAT6 program, resulting in a $15 million payment, with potential for an additional $465 million in future milestones [3][6] - Nurix continues to advance its collaborations with Gilead and Pfizer, expecting to achieve further research milestones [6][7] Cash Position - As of May 31, 2025, Nurix had cash and marketable securities totaling $485.8 million, down from $609.6 million as of November 30, 2024 [10][15]

Core Insights - Nurix Therapeutics has announced that Sanofi has exercised its option to exclusively license Nurix's STAT6 program, which includes the drug candidate NX-3911, a selective STAT6 degrader [2][3] - The collaboration agreement from 2019 has resulted in a total of $127 million received by Nurix, with the potential for an additional $465 million in development, regulatory, and commercial milestones [1][3] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for patients with cancer and inflammatory diseases [5][6] - The company utilizes its proprietary DEL-AI drug discovery platform to identify novel agents that induce degradation of specified drug targets, with a focus on E3 ligases [3][6] Product Development - NX-3911 is a potent, orally administered STAT6 degrader that has shown robust efficacy in preclinical models for atopic dermatitis and asthma, demonstrating anti-inflammatory effects comparable to a STAT6 gene knockout [3][4] - The STAT6 program also includes additional differentiated discovery-stage assets, representing further product opportunities within the collaboration with Sanofi [3] Financial Aspects - Under the collaboration agreement, Sanofi made an upfront payment of $55 million and an additional $22 million to expand the collaboration scope, with Nurix eligible for royalties on future sales [3] - Nurix retains the option to co-develop and co-promote up to two future products in the U.S., sharing profits and losses evenly with Sanofi [3]

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and ...